SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending after a post-earnings sell-off, with the community actively debating whether strong quarterly results and a share buyback are overshadowed by persistent concerns about high stock-based compensation and dilution, amid long-term optimism for AI/AR innovations.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its Q4 earnings report, where strong profitability and a strategic shift towards prudent risk management were met with a severe market sell-off due to conservative revenue guidance and prevailing fintech sector weakness. The community is sharply divided, with many calling the stock oversold and deeply undervalued while others express frustration over management's outlook and perceived manipulation.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as it opens its 30,000th store, including a new premium flagship, coinciding with rival Cotti Coffee reportedly ending its aggressive discount strategy. This development is driving community discussions around potential margin expansion and the company's significant undervaluation compared to competitors.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is plummeting after the abrupt departures of its CFO and general counsel amid an SEC accounting investigation, sparking intense community discussion on whether the severe market reaction presents a bargain opportunity or signals deeper issues akin to prior corporate collapses.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is seeing intense discussion around its pivotal role in the AI-nuclear nexus, fueled by its power development partnership with Meta and anticipated DOE plutonium awards, though persistent insider selling and its pre-revenue status are generating fierce debate and price swings.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

Recent exchange listings and extensive utility enhancements for BankrCoin's AI-powered trading agents on the Base ecosystem are driving intense community discussion, with many anticipating significant price discovery despite lingering "pump and dump" concerns.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is actively discussed after its latest earnings report, which saw an EPS beat but a revenue miss largely due to contract transitions and a government shutdown, leading to divided community sentiment with many investors calling the stock's decline an overreaction and a long-term buying opportunity given its substantial backlog in nuclear, space, and defense programs.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing issues with trial design and the use of natural history controls. The community is now intensely discussing the severe financial impact on the company and potential ramifications for its other gene therapy programs and the broader sector.

Haverty Furniture Cos., Inc. engages in the retail of residential furniture and accessories. Its products are Tempur-Pedic, Serta, Stearns and Foster, Beautyrest, and Sealy. The company was founded by James Joseph Haverty in 1885 and is headquartered in Atlanta, GA.

Haverty Furniture Cos., Inc. - Ordinary Shares - Class A

Haverty Furniture (HVT.A) is trending following a notable price jump, sparking significant community excitement and discussion about potential profit opportunities.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending amidst upcoming Q4 earnings and recent partnership announcements, including a new integration with Kikoff and strong speculation around a Hyundai white-label deal, which bulls believe will drive significant growth. However, persistent stock declines, perceived market manipulation by shorts and insiders, and community frustration with CEO Alex Timm's communication have created a highly polarized sentiment, despite the company's reported operational improvements and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America

Bank of America initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat reports...

Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2% - What's Next?

Inhibikase Therapeutics (NYSE:IKT) Shares Up 1.2% - What's Next...

Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0%

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...

Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright

HC Wainwright raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research report on Friday...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen

Wall Street Zen raised Inhibikase Therapeutics to a "sell" rating in a report on Saturday...

Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Friday...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Thursday...

Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT)

Cantor Fitzgerald initiated coverage on Inhibikase Therapeutics in a report on Thursday. They issued an "overweight" rating and a $4.00 price target on the stock...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

Inhibikase Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.65
Prev Close	$1.70
Open	$1.72
Dividend Yield	0.00%
50-Day Moving Average	$1.66
Beta	0.99
Avg. Volume	519,219.10
PE Ratio	-2.98

52-Week High	$3.32
52-Week Low	$1.33
Market Capitalization	$206.15M
EPS (Annual)	-$1.16
Price to Book	1.74
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IKT
Inhibikase Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IKT News

IKTInhibikase Therapeutics Inc